2. Females with histologically confirmed MBC whose disease is resistant to previous nonsteroidal aromatase inhibitors (letrozole or anastrozole), defined as: Recurrence while on or within 12 months after the end of adjuvant treatment with NSAI or Progression while on or within 1 month after the end of treatment with NSAI for advanced disease.